MX2007005649A - Carboxiamidas de azaindol. - Google Patents

Carboxiamidas de azaindol.

Info

Publication number
MX2007005649A
MX2007005649A MX2007005649A MX2007005649A MX2007005649A MX 2007005649 A MX2007005649 A MX 2007005649A MX 2007005649 A MX2007005649 A MX 2007005649A MX 2007005649 A MX2007005649 A MX 2007005649A MX 2007005649 A MX2007005649 A MX 2007005649A
Authority
MX
Mexico
Prior art keywords
azaindole
carboxamides
general formula
ht1a
accompanied
Prior art date
Application number
MX2007005649A
Other languages
English (en)
Inventor
Peter Gmeiner
Harald Hubner
Karin Schlotter
Dirk Schmidt
Monika Buchholz
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of MX2007005649A publication Critical patent/MX2007005649A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La invencion se refiere a derivados de azaindol de la formula general I: (ver Formula I) en la que X representa un grupo de la formula general X1: (ver Formula X1) Dichos compuestos tienen accion terapeutica para el tratamiento de enfermedades que van acompanadas por un metabolismo de dopamina danado y/o una transmision de senal 5-HT1a de serotonina anormal.
MX2007005649A 2004-11-12 2005-11-11 Carboxiamidas de azaindol. MX2007005649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004054634A DE102004054634A1 (de) 2004-11-12 2004-11-12 Azaindolcarboxamide
PCT/EP2005/012127 WO2006050976A1 (de) 2004-11-12 2005-11-11 Azaindolcarboxamide

Publications (1)

Publication Number Publication Date
MX2007005649A true MX2007005649A (es) 2007-07-09

Family

ID=35929547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005649A MX2007005649A (es) 2004-11-12 2005-11-11 Carboxiamidas de azaindol.

Country Status (15)

Country Link
US (1) US20070299091A1 (es)
EP (1) EP1771448A1 (es)
JP (1) JP2008519797A (es)
KR (1) KR20070083843A (es)
CN (1) CN101056878A (es)
AU (1) AU2005303904A1 (es)
BR (1) BRPI0517846A (es)
CA (1) CA2575668A1 (es)
DE (1) DE102004054634A1 (es)
EA (1) EA200700909A1 (es)
IL (1) IL180317A0 (es)
MX (1) MX2007005649A (es)
NO (1) NO20072601L (es)
WO (1) WO2006050976A1 (es)
ZA (1) ZA200700252B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
AU2007354861B2 (en) 2007-06-15 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use
CN102892768A (zh) 2009-12-30 2013-01-23 艾科尔公司 被取代的吡咯并氨基嘧啶化合物
NZ702571A (en) 2012-06-29 2017-02-24 Pfizer 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
US11299476B2 (en) 2016-03-14 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CN106279071B (zh) * 2016-08-10 2019-01-04 广东东阳光药业有限公司 苯基哌嗪衍生物及其使用方法和用途
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
CN111801330B (zh) 2018-01-26 2024-04-05 盐野义制药株式会社 具有多巴胺d3受体拮抗作用的稠环化合物
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
US11337971B2 (en) 2018-09-11 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340113C (en) * 1988-05-24 1998-11-03 Magid A. Abou-Gharbia Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
ES2027898A6 (es) * 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina.
PL310443A1 (en) * 1993-03-01 1995-12-11 Merck Sharp & Dohme Derivatives of pyrolo-pyridine
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
AU2003246356A1 (en) * 2002-07-04 2004-01-23 Schwarz Pharma Ag Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases
CA2498936C (en) * 2002-09-14 2013-02-12 Gov't Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Structurally rigid dopamine d3 receptor selective ligands and process for making them
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
CA2525502C (en) * 2003-05-21 2012-12-18 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
SE0401655D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
US20070299091A1 (en) 2007-12-27
BRPI0517846A (pt) 2008-10-21
KR20070083843A (ko) 2007-08-24
CN101056878A (zh) 2007-10-17
CA2575668A1 (en) 2006-05-18
EP1771448A1 (de) 2007-04-11
NO20072601L (no) 2007-05-22
JP2008519797A (ja) 2008-06-12
WO2006050976A1 (de) 2006-05-18
AU2005303904A1 (en) 2006-05-18
IL180317A0 (en) 2007-06-03
ZA200700252B (en) 2009-05-27
DE102004054634A1 (de) 2006-05-18
EA200700909A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
MX2007005649A (es) Carboxiamidas de azaindol.
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
TW200611695A (en) Pyrrolopyridine derivatives
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2009002920A (es) Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2007257423A8 (en) Purine analogs
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
GEP20125458B (en) Matrix metalloproteinase inhibitors
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
MX2009011215A (es) Derivados de triazolopiridina carboxamida, su preparacion y su aplicacion terapeutica.
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200504045A (en) Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament

Legal Events

Date Code Title Description
FA Abandonment or withdrawal